Continued access to deucravacitinib for people who completed prior studies
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study provides continued access to the medication deucravacitinib for people who have completed one of several earlier studies. It aims to offer ongoing treatment for conditions like lupus, Sjogren's syndrome, or psoriasis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed a qualifying parent study (e.g., IM011-246, IM011-247, IM011-1069, IM011-126, IM011-1128, or IM011-1071).
- You must not have any disease or medical condition that your doctor thinks would make it unsafe for you to participate.
- You must not have any condition that could interfere with the safety data collection.
- Your doctor must consider you suitable for the study for any other reason.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
This study looks at how well deucravacitinib works for people with moderate to severe plaque psoriasis in real-life settings in Italy. It follows patients who have already started the treatment to see how they are doing.
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
This trial provides early access to a medication called upadacitinib for people who have no other suitable treatment options and cannot join a clinical trial. Upadacitinib may help manage certain conditions when standard treatments have not worked.
This study lets people who have already finished a previous trial of deucravacitinib continue taking the medicine. It is for adults with lupus, including skin-only forms of the disease, to see if long-term treatment remains safe and helpful.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.